- Home
- GENK vs RLMD Comparison
GENK vs RLMD Comparison
Compare GENK & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- RLMD
- Stock Information
- Founded
- GENK 2011
- RLMD 2004
- Country
- GENK United States
- RLMD United States
- Employees
- GENK N/A
- RLMD N/A
- Industry
- GENK Restaurants
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- RLMD Health Care
- Exchange
- GENK Nasdaq
- RLMD Nasdaq
- Market Cap
- GENK 20.4M
- RLMD 20.3M
- IPO Year
- GENK 2023
- RLMD N/A
- Fundamental
- Price
- GENK $3.50
- RLMD $0.59
- Analyst Decision
- GENK Strong Buy
- RLMD Buy
- Analyst Count
- GENK 2
- RLMD 3
- Target Price
- GENK $7.00
- RLMD $5.00
- AVG Volume (30 Days)
- GENK 93.0K
- RLMD 194.9K
- Earning Date
- GENK 08-06-2025
- RLMD 08-07-2025
- Dividend Yield
- GENK 0.87%
- RLMD N/A
- EPS Growth
- GENK N/A
- RLMD N/A
- EPS
- GENK N/A
- RLMD N/A
- Revenue
- GENK $216,137,000.00
- RLMD N/A
- Revenue This Year
- GENK $17.79
- RLMD N/A
- Revenue Next Year
- GENK $15.87
- RLMD N/A
- P/E Ratio
- GENK N/A
- RLMD N/A
- Revenue Growth
- GENK 10.67
- RLMD N/A
- 52 Week Low
- GENK $3.16
- RLMD $0.24
- 52 Week High
- GENK $10.33
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- GENK 38.00
- RLMD 44.69
- Support Level
- GENK $3.25
- RLMD $0.58
- Resistance Level
- GENK $4.16
- RLMD $0.63
- Average True Range (ATR)
- GENK 0.37
- RLMD 0.05
- MACD
- GENK -0.08
- RLMD -0.01
- Stochastic Oscillator
- GENK 13.22
- RLMD 8.09
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.